{"filing":{"accession_number":"0001104659-26-101231","cik":"0001768946","ticker":null,"company_name":"Biophytis SA","form":"6-K","filing_date":"2026-08-26","report_date":"2026-08-26","primary_document":"tm2624101d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768946/000110465926101231/tm2624101d1_6k.htm"},"events":[{"id":29681,"run_id":27195,"accession_number":"0001104659-26-101231","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Biophytis announces the rollout and formalization of a joint venture (Biophytis Biopharmaceutical Holding LTD) created in June 2026 with Asian partners, involving transfer of intellectual property (BIO101 patents in China, Japan, South Korea), a licensing agreement with single-digit royalties, and committed funding of up to $20 million ($3 million initial tranche, $10 million in year one). This constitutes a material change of control and strategic partnership affecting the company's capital structure (29% equity stake retained) and development strategy for a key asset (BIO101 for sarcopenia), warranting classification as M\u0026A activity.","company_name":"Biophytis SA","ticker":null,"filing_date":"2026-08-26","form":"6-K","submitted_at":null,"items":[{"id":32051,"accession_number":"0001104659-26-101231","item_number":"EX-99.1","item_title":"tm2624101d1_ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Biophytis announces the rollout and formalization of a joint venture (Biophytis Biopharmaceutical Holding LTD) created in June 2026 with Asian partners, involving transfer of intellectual property (BIO101 patents in China, Japan, South Korea), a licensing agreement with single-digit royalties, and committed funding of up to $20 million ($3 million initial tranche, $10 million in year one). This constitutes a material change of control and strategic partnership affecting the company's capital structure (29% equity stake retained) and development strategy for a key asset (BIO101 for sarcopenia), warranting classification as M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-26T16:09:38.232379+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32051,"accession_number":"0001104659-26-101231","item_number":"EX-99.1","item_title":"tm2624101d1_ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Biophytis announces the rollout and formalization of a joint venture (Biophytis Biopharmaceutical Holding LTD) created in June 2026 with Asian partners, involving transfer of intellectual property (BIO101 patents in China, Japan, South Korea), a licensing agreement with single-digit royalties, and committed funding of up to $20 million ($3 million initial tranche, $10 million in year one). This constitutes a material change of control and strategic partnership affecting the company's capital structure (29% equity stake retained) and development strategy for a key asset (BIO101 for sarcopenia), warranting classification as M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-26T16:09:38.232379+00:00","company_name":"Biophytis SA","ticker":null,"filing_date":"2026-08-26"}]}